(Q37426243)

20 August 2017

1 reference

title

Managing adverse events in the use of bevacizumab and chemotherapy (English)

1 reference

20 August 2017

1 reference

1 reference

Elaine Blowers

1

1 reference

20 August 2017

Kate Hall

series ordinal

2

1 reference

20 August 2017

language of work or name

1 reference

1 March 2009

1 reference

British Journal of Nursing

20 August 2017

published in

1 reference

20 August 2017

volume

18

1 reference

20 August 2017

issue

6

1 reference

20 August 2017

page(s)

351-6, 358

1 reference

VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.12968%2FBJON.2009.18.6.40767

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FBJON.2009.18.6.40767

Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FBJON.2009.18.6.40767

Mechanisms of adverse effects of anti-VEGF therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FBJON.2009.18.6.40767

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FBJON.2009.18.6.40767

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FBJON.2009.18.6.40767

Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FBJON.2009.18.6.40767

Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FBJON.2009.18.6.40767

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FBJON.2009.18.6.40767

High frequency of LMAN1 abnormalities in colorectal tumors with microsatellite instability

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FBJON.2009.18.6.40767

Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FBJON.2009.18.6.40767

10.12968/BJON.2009.18.6.40767

21 January 2018

Identifiers

DOI

0 references

1 reference